RxDoctor Payments Data

Wendell Colberg, MD

Allergy · Pensacola, FLNPI 1407824568

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 52 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by AstraZeneca at 54.8% of the total. 2024 is the largest year on record at $980, 2.9 times the $338 reported in 2019. That places this record below the midpoint for allergy clinicians in FL, where the typical reported total is $3,444.

$3,444in general payments, 2019–2025

Across 52 payments — averaging $66.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$914
  • Grifols USA, LLC$179
  • Regeneron Healthcare Solutions, Inc.$99
  • Sanofi$94
  • Pfizer$90
  • plus $182 from 4 others

What the payments were for

  • Food & beverage$3,444100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,444 in reported general payments places this provider in the 50th percentile of 56 allergy providers in Florida.

See all allergy providers in Florida

Medicare billing

Part B allowed, 2024
$58,509
Medicare patients
166
Services billed
3,811

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab11$40,811
Breo ElliptaFluticasone/Vilanterol28$22,659
Arnuity ElliptaFluticasone Furoate26$9,535
Azelastine Hcl141$6,209
Epinephrine25$4,678
Advair HfaFluticasone Propion/Salmeterol11$3,394
Fluticasone-SalmeterolFluticasone Propion/Salmeterol17$2,614
Ipratropium Bromide43$1,899
Fluticasone Propionate87$1,831
Montelukast Sodium153$1,412
Ventolin HfaAlbuterol Sulfate23$1,304
Albuterol Sulfate HfaAlbuterol Sulfate30$1,241
Famotidine21$320
Levocetirizine Dihydrochloride13$237
Hydroxyzine Hcl12$214

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta, Arnuity Ellipta$914$32,19454 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 56 allergy providers in Florida.

Other allergy in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →